Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Masonic Cancer Center, University of Minnesota National Cancer Institute (NCI) |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00623077 |
RATIONALE: A peripheral blood stem cell transplant or bone marrow transplant using stem cells from the patient may be able to replace immune cells that were destroyed by chemotherapy and image-guided intensity-modulated radiation therapy used to kill tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of bone marrow radiation therapy followed by an autologous stem cell transplant in treating patients with high-risk or relapsed solid tumors.
Condition | Intervention | Phase |
---|---|---|
Brain and Central Nervous System Tumors Kidney Cancer Liver Cancer Retinoblastoma Sarcoma Unspecified Adult Solid Tumor, Protocol Specific Unspecified Childhood Solid Tumor, Protocol Specific |
Biological: filgrastim Biological: sargramostim Drug: busulfan Drug: etoposide Drug: ifosfamide Drug: melphalan Drug: thiotepa Other: pharmacological study Procedure: autologous bone marrow transplantation Procedure: autologous hematopoietic stem cell transplantation Procedure: peripheral blood stem cell transplantation Procedure: positron emission tomography Radiation: intensity-modulated radiation therapy Radiation: tomotherapy Radiation: total marrow irradiation |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment |
Official Title: | Dose Escalation of Total Marrow Irradiation Added to an Alkylator-Intense Conditioning Regimen for Patients With High Risk or Relapsed Solid Tumors |
Estimated Enrollment: | 18 |
Study Start Date: | July 2005 |
Estimated Primary Completion Date: | June 2010 (Final data collection date for primary outcome measure) |
OBJECTIVES:
Primary
Secondary
OUTLINE:
If the aspirate or biopsy is morphologically free of tumor cells and demonstrates > 20% cellularity, then patients receive sargramostim (GM-CSF) daily for 5 days followed by bone marrow harvest.
NOTE: *Patients with primary CNS tumors do not receive TMI but are eligible to receive chemotherapy and hematopoietic progenitor cell rescue in accordance with the protocol.
Patients undergo bone mineral density studies at baseline and at days 60, 120, and 180 post transplantation.
Patients also undergo blood sample collection periodically during study for pharmacokinetic analysis of busulfan.
Patients undergo PET scans at baseline and on day 60.
After completion of study therapy, patients are followed at days 180 and 365 and then periodically thereafter.
Ages Eligible for Study: | up to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Histologically confirmed diagnosis of 1 of the following malignancies:
Ewing sarcoma family tumors meeting ≥ 1 of the following criteria:
Renal tumors meeting either of the following criteria:
Hepatoblastoma meeting ≥ 1 of the following criteria:
Rhabdomyosarcoma meeting ≥ 1 of the following criteria:
Soft tissue sarcomas meeting either of the following criteria:
Primary malignant brain neoplasms meeting ≥ 1 of the following criteria:
Retinoblastoma meeting ≥ 1 of the following criteria:
No evidence of disease or stable, non-progressive disease, defined as non-progressive abnormalities by physical examination, CT scan, and/or MRI
Able to receive total marrow irradiation via tomographic radiotherapy (as determined by radiation oncology staff)
PATIENT CHARACTERISTICS:
PRIOR CONCURRENT THERAPY:
United States, Minnesota | |
Masonic Cancer Center at University of Minnesota | Recruiting |
Minneapolis, Minnesota, United States, 55455 | |
Contact: Clinical Trials Office - Masonic Cancer Center at University o 612-624-2620 |
Principal Investigator: | Michael R. Verneris, MD | Masonic Cancer Center, University of Minnesota |
Study ID Numbers: | CDR0000586064, UMN-2005LS023, UMN-MT2004-30 |
Study First Received: | February 22, 2008 |
Last Updated: | February 6, 2009 |
ClinicalTrials.gov Identifier: | NCT00623077 History of Changes |
Health Authority: | Unspecified |
metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor childhood hepatoblastoma recurrent childhood liver cancer stage IV childhood liver cancer adult primary liver cancer previously treated childhood rhabdomyosarcoma recurrent childhood rhabdomyosarcoma previously untreated childhood rhabdomyosarcoma metastatic childhood soft tissue sarcoma recurrent childhood soft tissue sarcoma recurrent adult soft tissue sarcoma stage IV adult soft tissue sarcoma recurrent Wilms tumor and other childhood kidney tumors stage IV Wilms tumor |
stage V Wilms tumor rhabdoid tumor of the kidney stage IV renal cell cancer adult anaplastic astrocytoma adult anaplastic ependymoma adult anaplastic meningioma adult anaplastic oligodendroglioma adult diffuse astrocytoma adult giant cell glioblastoma adult gliosarcoma adult pilocytic astrocytoma adult pineal gland astrocytoma adult subependymal giant cell astrocytoma adult subependymoma adult brain stem glioma |
Retinal Neoplasms Glioblastoma Liver Diseases Neuroectodermal Tumors, Primitive Urogenital Neoplasms Central Nervous System Neoplasms Retinoblastoma Urologic Neoplasms Neoplasms, Connective and Soft Tissue Wilms' Tumor Neuroepithelioma Glioma Hepatoblastoma Kidney Diseases Etoposide |
Nervous System Neoplasms Rhabdomyosarcoma Digestive System Neoplasms Astrocytoma Eye Neoplasms Ewing's Sarcoma Hemangiopericytoma Thiotepa Carcinoma Brain Neoplasms Neuroectodermal Tumors Brain Stem Glioma, Childhood Malignant Mesenchymal Tumor Sarcoma Gastrointestinal Neoplasms |
Retinal Neoplasms Melphalan Liver Diseases Molecular Mechanisms of Pharmacological Action Immunologic Factors Antineoplastic Agents Physiological Effects of Drugs Neoplasms, Nerve Tissue Urogenital Neoplasms Central Nervous System Neoplasms Urologic Neoplasms Retinoblastoma Liver Neoplasms Neoplasms, Connective and Soft Tissue Neoplasms by Site |
Urologic Diseases Kidney Neoplasms Therapeutic Uses Neoplasms, Germ Cell and Embryonal Kidney Diseases Alkylating Agents Retinal Diseases Nervous System Neoplasms Neoplasms by Histologic Type Digestive System Neoplasms Eye Neoplasms Eye Diseases Nervous System Diseases Immunosuppressive Agents Pharmacologic Actions |